Frontotemporal dementia (FTD) represents a spectrum of neurodegenerative disorders characterized by progressive atrophy of the frontal and temporal lobes. A significant proportion of FTD cases are driven by tau pathology, classified as FTD-tau or primary tauopathies. These disorders involve the selective vulnerability of specific neuronal populations to tau protein misfolding, aggregation, and propagation. Understanding which neurons are vulnerable and why is crucial for developing targeted therapeutic interventions.
- Pathology: Characterized by 3-repeat (3R) tau aggregates forming Pick bodies
- Clinical Presentation: Behavioral variant FTD with prominent personality changes
- Vulnerable Regions: Frontal and anterior temporal cortices, hippocampal formation
- Pathology: 4-repeat (4R) tau in astrocytic plaques and neuronal threads
- Clinical Presentation: Asymmetric parkinsonism, apraxia, cortical sensory loss
- Vulnerable Regions: Basal ganglia, substantia nigra, cortical motor areas
- Pathology: 4R tau in globose neurofibrillary tangles
- Clinical Presentation: Vertical gaze palsy, postural instability, parkinsonism
- Vulnerable Regions: Brainstem nuclei, basal ganglia, subthalamic nucleus
- Early tau accumulation in upper cortical layers with progression to deeper layers
- Dendritic dysfunction precedes somatic tau deposition
- Large axonal projections make these neurons particularly vulnerable
- Impaired axonal transport contributes to degeneration
- Early tau pathology in the entorhinal cortex (Braak stage I-II)
- Stellate neurons are selectively vulnerable
- Critical hub for tau propagation to the hippocampus
- Grid cell dysfunction contributes to spatial memory deficits
- Giant pyramidal neurons in primary motor cortex
- Early involvement in corticobasal degeneration
- Axonal degeneration affects corticospinal tract
- Significant tau burden in all FTD-tau subtypes
- Selective vulnerability to tau-induced synaptic loss
- Impaired place cell function affects spatial navigation
- Relative sparing in early stages
- Later involvement in disease progression
- Adult neurogenesis may be affected
- Dopaminergic neuron loss in PSP and CBD
- Contributes to parkinsonian features
- Tau pathology in Lewy body-like inclusions
- Cholinergic neurons vulnerable in FTD-tau
- Contributes to cognitive dysfunction
- Interaction with tau and amyloid pathology
- Particularly vulnerable in PSP
- Large neurons with extensive connectivity
- Tau accumulation in neurofibrillary tangles
- Highly vulnerable in PSP
- 4R tau in neurofibrillary tangles
- Contributes to motor dysfunction
¶ Tau Misfolding and Aggregation
Isoform-Specific Pathology:
- 3R tau: Predominant in Pick's disease
- 4R tau: Dominant in CBD and PSP
- Mixed 3R/4R: Found in AD and some FTD cases
Aggregation Pathways:
- Hyperphosphorylation promotes tau monomer aggregation
- Seeded templated growth of tau fibrils
- Prion-like propagation between neurons
Metabolic Vulnerability:
- High energy demands of large neurons
- Extensive mitochondrial networks
- Calcium dysregulation
Structural Vulnerability:
- Long axonal projections requiring efficient transport
- High synaptic activity
- Large dendritic trees
Molecular Susceptibility:
- Specific transcription profiles (FOXP1, C9orf72)
- Protein homeostasis differences
- Lipid metabolism variations
Trans-synaptic Transmission:
- Tau propagates along neuronal circuits
- Synaptic activity enhances spread
- Anatomically connected regions show correlated pathology
Extracellular Vesicles:
- Tau secreted in exosomes
- Microglia-mediated spread
- CSF circulation
- Pre-synaptic tau disrupts neurotransmitter release
- Post-synaptic tau affects receptor trafficking
- Spine loss precedes cell death
- Tau accumulation in axons impairs transport
- Mitochondrial trafficking disruption
- Neurotrophic factor deprivation
- Impaired autophagy-lysosomal pathway
- Ubiquitin-proteasome system dysfunction
- ER stress response activation
- Tau channels increase membrane permeability
- Mitochondrial calcium overload
- Excitotoxicity
Active Immunization:
- AADvac1 (Axon Neurodegeneration)
- ACI-35 (Lipids-based tau vaccine)
Passive Immunization:
- Anti-phospho-tau antibodies (phase 2/3 trials)
- Antibody-mediated tau clearance
- Prevention of cell-to-cell spread
- Methylene blue derivatives
- Phenothiazines
- Natural compounds (curcumin, epigallocatechin gallate)
- GSK-3β inhibitors
- CDK5 inhibitors
- Tyrosine kinase inhibitors
- Mitochondrial stabilizers
- Calcium channel modulators
- Synaptic plasticity enhancers
- Induced pluripotent stem cell (iPSC)-derived neurons
- Tau transgenic mouse neurons
- Organoid models
- P301S tauopathy mouse
- rTg4510 inducible model
- AAV-mediated tau expression
- CSF total tau and phospho-tau
- Neurofilament light chain (NfL)
- Tau fragments in blood
- Tau PET (Flortaucipir, MK-6240)
- Structural MRI for atrophy patterns
- Diffusion tensor imaging
- Dickson DW et al. (2022). Neuropathology of Frontotemporal Dementia, Corticobasal Degeneration, and Progressive Supranuclear Palsy. Acta Neuropathologica
- Rossi G, Tagliavini F. (2021). Tau Propagation in Frontotemporal Dementia. Nature Reviews Neurology
- Lee VM, Goedert M, Trojanowski JQ. (2021). Neurodegenerative tauopathies. Annual Review of Neuroscience
- Arendt T et al. (2016). Tau pathology is the primary determinant of neuronal dysfunction in Alzheimer's disease. Brain
- Jellinger KA. (2019). Tauopathies. Handbook of Clinical Neurology
- Arai T et al. (2001). Distinct isoforms of tau aggregated in neurons and glia. Journal of Alzheimer's Disease
- Buee L, Delacourte A. (2019). Tau in physiology and pathology. Nature Reviews Neuroscience
- Ballatore C, Lee VM, Trojanowski JQ. (2007). Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Reviews Neuroscience